The ACTH × DHEAS product as an ancillary biomarker of mild autonomous cortisol secretion in adrenal incidentalomas
Introduction: Mild autonomous cortisol secretion (MACS) is usually classified by the 1-mg overnight dexamethasone suppression test (DST). However, a single post-DST cortisol value may not fully capture the chronicity or biological relevance of cortisol autonomy. Although adrenocorticotropic hormone (ACTH) and dehydroepiandrosterone sulfate (DHEAS) reflect different but biologically linked components of hypothalamic–pituitary–adrenal (HPA) axis suppression, their combined assessment has not been sufficiently evaluated in adrenal incidentalomas.
Objective: To evaluate the association between the ACTH × DHEAS product and DST-defined cortisol autonomy and to explore its potential role as an ancillary biochemical marker in adrenal incidentalomas.
Methods: This retrospective study included 157 patients classified as having MACS or a nonfunctioning adrenal adenoma based on post-DST cortisol levels. Patients with overt endocrine syndromes, malignant or rare adrenal lesions, and ARMC5-positive disease were excluded. Correlation analyses, sex-adjusted multivariable logistic regression, exploratory receiver operating characteristic analyses, and a DeLong test were performed.
Results: MACS was present in 79 patients (50.3%). Patients with MACS had larger tumors, higher basal and post-DST cortisol, and lower ACTH, DHEAS, and ln(ACTH × DHEAS). ln(ACTH × DHEAS) was inversely correlated with post-DST cortisol and larger tumor size. After adjustment for age, sex, basal cortisol, and larger tumor size, lower ln(ACTH × DHEAS) remained independently associated with MACS (odds ratio = 0.473, 95% CI: 0.304–0.737, p = 0.001). The corrected ln(ACTH × DHEAS) showed moderate discrimination (area under the curve = 0.693) but did not significantly outperform −DHEAS alone.
Conclusion: ln(ACTH × DHEAS) may serve as a practical ancillary marker of chronic HPA-axis suppression, particularly in borderline or discordant cases. It should not replace DST or DHEAS alone, and prospective outcome-based validation is required before clinical implementation.
- Owei L, Wachtel H. The Landmark Series: Evaluation and Management of Adrenal Incidentalomas. Ann Surg Oncol. 2025;32(7):4712-4719. doi: 10.1245/s10434-025-17296-8
- Araujo-Castro M, Iriarte-Durán MB, Parra-Ramírez P, Donato S. Management of adrenal incidentalomas: who, why and how? Curr Opin Endocrinol Diabetes Obes. 2025;32(5):210-221. doi: 10.1097/MED.0000000000000917
- Kouroglou E, Tsiama V, Stroumpouli E, et al. Evaluation of adrenal incidentalomas: Current approaches, caveats, and unexplored issues. World J Radiol. 2026;18(4):119833. doi: 10.4329/wjr.v18.i4.119833
- Prete A, Bancos I. Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches. Nat Rev Endocrinol. 2024;20(8):460-473. doi: 10.1038/s41574-024-00984-y
- Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42. doi: 10.1093/ejendo/lvad066
- Ueland G, Grinde T, Methlie P, Kelp O, Løvås K, Husebye ES. Diagnostic testing of autonomous cortisol secretion in adrenal incidentalomas. Endocr Connect. 2020;9(10):963-970. doi: 10.1530/EC-20-0419
- Findling JW, Raff H. Recognition of Nonneoplastic Hypercortisolism in the Evaluation of Patients With Cushing Syndrome. J Endocr Soc. 2023;7(8):bvad087. doi: 10.1210/jendso/bvad087
- Dennedy MC, Annamalai AK, Prankerd-Smith O, et al. Low DHEAS: A sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas. J Clin Endocrinol Metab. 2017;102(3):786-792. doi: 10.1210/jc.2016-2718
- Mirica A, Tilici DM, Paun DL, Arnautu AM, Nimigean V, Paun S. Adrenal Incidentaloma: From Silent Diagnosis to Clinical Challenge. Biomedicines. 2025;13(9):2298. doi: 10.3390/biomedicines13092298
- Gjerstad JK, Lightman SL, Spiga F. Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility. Stress. 2018;21(5):403-416. doi: 10.1080/10253890.2018.1470238
- Puvaneswaralingam S, Kjellbom A, Lindgren O, Löndahl M, Olsen H. ACTH following overnight dexamethasone suppression can be used in the verification of autonomous cortisol secretion in patients with adrenal incidentalomas. Clin Endocrinol. 2021;94(2):168-175. doi: 10.1111/cen.14357
- Yener S, Tuna G, Sahin H, et al. Estimation of cortisol exposure in patients with adrenal incidentalomas. BMC Endocr Disord. 2025;25(1):266. doi: 10.1186/s12902-025-02090-0
- Al-Waeli D, Alidrisi H, Mansour A. Utilizing dehydroepiandrosterone sulfate and its ratio for detecting mild autonomous cortisol excess in patients with adrenal incidentaloma. J Med Life. 2023;16(10):1456-1461. doi: 10.25122/jml-2023-0092
- Iwamoto Y, Tatsumi F, Itoh T, et al. Usefulness of cortisol/ACTH ratio (CAR) for diagnosis of cushing’s syndrome: comparison of CAR with findings in dexamethasone suppression test. Sci Rep. 2022;12(1):17680. doi: 10.1038/s41598-022-22676-1
- Clarke SA, Eng PC, Comninos AN, et al. Current Challenges and Future Directions in the Assessment of Glucocorticoid Status. Endocr Rev Endocr Soc. 2024;45(6):795-817. doi: 10.1210/endrev/bnae016
- Olsen H, Olofsson L, Mjöman M. Cortisol secretion from adrenal adenomas discovered as incidentalomas is responsive to ACTH. Clin Endocrinol. 2014;80(3):335-341. doi: 10.1111/cen.12295
- Genere N, Kaur RJ, Athimulam S, et al. Interpretation of Abnormal Dexamethasone Suppression Test is Enhanced with Use of Synchronous Free Cortisol Assessment. J Clin Endocrinol Metab. 2022;107(3):E1221-E1230. doi: 10.1210/clinem/dgab724
- Akirov A, Dery L, Fleseriu M, et al. Cushing’s syndrome in women: age-related differences in etiology and clinical picture. Pituitary. 2023;26(1):144-151. doi: 10.1007/s11102-022-01292-2
- Araujo-Castro M, García Cano A, Jiménez Mendiguchía L, Escobar-Morreale HF, Valderrábano P. Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion. Sci Rep. 2021;11(1):20539. doi: 10.1038/s41598-021-00011-4
- Tabarin A, Espiard S, Deutschbein T, et al. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial. Lancet Diabetes Endocrinol. 2025;13(7):580-590. doi: 10.1016/S2213-8587(25)00062-2
- Ren X, Nan M, Zhang X. Evaluating the efficacy of surgical and conservative approaches in mild autonomous cortisol secretion: a meta-analysis. Front Endocrinol. 2024;15:1399311. doi: 10.3389/fendo.2024.1399311
- De Alcubierre D, Ferrari D, Tomaselli A, et al. Long-term cardiac effects of adrenalectomy versus surveillance in mild cortisol excess: 5-year results from the prospective ITACA study. Eur J Endocrinol. 2026;194(2):170-184. doi: 10.1093/ejendo/lvag018
- Young DG, Skibinski G, Mason JI, James K. The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor beta 1 (TGF-β1) levels in normal healthy blood donors. Clin Exp Immunol. 1999;117(3):476-481. doi: 10.1046/j.1365-2249.1999.01003.x